Series CHealthtech·September 8, 2026NotableSignal 64 ·

Forus Raises $150M Series C at $3B Valuation

Company: Forus
Funding stage: Series C
Amount: $150 million
Date: September 8, 2026
Location: 🇺🇸 the US
Sector: Healthcare Automation
Investors: Bain Capital Ventures, Accel, Thrive Capital, General Catalyst, Redpoint Ventures, BoxGroup, Pear VC

What happened

Healthcare automation startup Forus raised $150 million in a Series C funding round at a $3 billion valuation. Bain Capital Ventures led the investment, with participation from Accel, Thrive Capital, General Catalyst, Redpoint Ventures, BoxGroup, and Pear VC.

Why it matters

Bain Capital Ventures leading alongside a syndicate of top-tier funds demonstrates strong conviction in healthcare automation scaling into multi-billion-dollar outcomes. A $3B valuation at Series C sets a high benchmark for healthtech software platforms automating operational workflows.

What to watch

Watch whether Forus can expand contract sizes across major hospital networks to justify its premium valuation.

VCBites Signal

76/ 100

Major signal

Why this score: A $150M Series C led by Bain Capital Ventures at a $3B valuation, backed by top-tier firms including Accel and Thrive Capital, represents a landmark mega-round for healthtech.

VCBites' internal significance rating (0-100) — our editorial read, not a market-standard metric. VC Bites' assessment of the significance of this development to the venture ecosystem. Not investment advice.

Who should care?

Healthtech Founders
VC Investors
Healthcare Executives
Growth Investors

Source

This is an original short summary. Read the full reporting at the original source.

Read the original story on Bloomberg

Share the signal

VC Bites

Forus Raises $150M Series C at $3B Valuation

VCBITES SIGNAL: 76 / 100

Why it matters

VC Bites · Venture capital signals, explained.

The post text is copied to your clipboard so you can paste it alongside the link.

More Healthtech bites

UndisclosedHealthtechCanada·6d agoBackgroundSignal 38 ·

DropGenie raises $5M USD

Biotech startup DropGenie has secured $5 million USD in funding with backing from BDC. The company operates in Montréal and Boston to accelerate biological data extraction.

Why it matters

Operating across Montréal and Boston enables DropGenie to bridge Canadian research capabilities with established US biopharma networks.

What to watch

Scaling of biological data extraction capabilities and expansion into US commercial partnerships.

Read bite Source · BetaKit

UndisclosedHealthtech·13d agoNotableSignal 46

Even Healthcare reaches $300M valuation in Khosla Ventures-led round

Even Healthcare reached a $300 million valuation in a new financing round led by Khosla Ventures. The company intends to use the capital to expand its hospital network in India.

Why it matters

Khosla Ventures' backing of Even Healthcare at a $300 million valuation signals sustained tier-1 US investor appetite for tech-enabled physical healthcare networks in India. Blending digital management with physical hospital infrastructure represents a capital-intensive evolution of standard healthtech delivery in emerging markets.

What to watch

Whether healthtech operators expanding into physical hospital footprints can sustain software-like margins while managing heavy capital expenditures.

Read bite Source · TechCrunch

Series AHealthtechCanada·17d agoNotableSignal 59 ·

Altay Therapeutics Closes $37M Series A

Altay Therapeutics, Inc. closed a $37 million Series A financing round to advance its DX5057 drug candidate for FSHD. The financing was co-led by Sound and supported by SOLVE FSHD.

Why it matters

Dedicated funding for rare disease targets continues to attract substantial early-stage capital when backed by specialized funds. A $37 million Series A provides sufficient runway to push lead candidate DX5057 into initial clinical validation phases.

What to watch

Clinical safety and preliminary efficacy data readouts from early trials of lead candidate DX5057.

Read bite Source · Financial Post